TAVR Device Focus As Emboline And VasoStitch Merger Spawns CardioLogical Solutions

In short

A new company, CardioLogical Solutions, has resulted from the merger of Emboline and VasoStitch. CardioLogical is focusing its efforts on developing accessory devices for the emergent transcatheter aortic valve implantation/replacement market.

Background

The large-hole access and closure technologies of VasoStitch and the aortic embolic protection technologies of Emboline form the initial core of a family of accessory devices offered by CardioLogical Solutions to address the clinical needs of emerging interventional cardiology procedures. Added to these is a novel approach to preventing contrast nephropathy during cardiovascular procedures. The technologies of CardioLogical Solutions are derived from intellectual property invented by serial entrepreneur Amir Belson, M.D., founder of NeoGuide Systems, Vascular Pathways, Zipline Medical, Thermocure and Radguard Medical and the force behind this new entity.

The recent emergence of transcatheter aortic valve replacement (TAVR) therapies has created a critical need for non-surgical, large-hole (>12 Fr) access and closure technologies, aortic embolic protection devices for prevention of stroke and other ischemic complications, and prevention of contrast nephropathy. The combined potential for these three markets where there exists now a strong clinical need is estimated at $2 to 3 billion.

Financial details of the merger were not disclosed, but what we do know is that David W. J. Smith, previously president and CEO of VasoStitch, is chief executive officer of the new business.

Company comments 

“Recent developments in interventional cardiology have created compelling opportunities for new types of procedural accessory devices,” said Dr. Belson. “Specifically, the recent emergence of transcatheter aortic valve replacement (TAVR) therapies has created a critical need for non-surgical, large-hole (>12 Fr) access and closure technologies, aortic embolic protection devices for prevention of stroke and other ischemic complications, and prevention of contrast nephropathy. The combined potential of these markets where there exists now a strong clinical need is estimated at $2 to 3 billion annually, and this is the immediate focus of CardioLogical Solutions.”

“Merging these companies will both create cost-efficiencies and enhance the value of the combined enterprise,” added David W. J. Smith, CardioLogical Solutions’ CEO. “The broad portfolio of CardioLogical Solutions represents the most comprehensive range of accessory products for the TAVR community. Our technologies address the three biggest clinical needs in TAVR, with superior technologies and a broad intellectual property portfolio.”

Regulatory status 

CardioLogical Solutions’ products are not available for sale in the United States or Europe at this time.

Source: CardioLogical Solutions, Inc., Business Wire